# Effect of Hepatic Impairment on LDK378 Pharmacokinetics

> **NCT01950481** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Normal Hepatic Function
- Impaired Hepatic Function

## Interventions

- **DRUG:** LDK378

## Key facts

- **NCT ID:** NCT01950481
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01950481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01950481, "Effect of Hepatic Impairment on LDK378 Pharmacokinetics". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01950481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*